Market News

CinCor Nosedives after Baxdrostat Disappoints in Phase 2

Shares of clinical-stage biopharmaceutical company CinCor Pharma (NASDAQ:CINC) are tanking today after topline results from a Phase 2 study of baxdrostat for the treatment of uncontrolled hypertension (in patients taking up to two medications) indicated the drug failed to meet its primary endpoint.

The safety and tolerability profile of the drug though came in consistent with the previous Phase 2 data in resistant hypertension.

The company now plans to meet with the U.S. FDA in January 2023 to discuss its Phase 3 plans. Further, it anticipates starting a Phase 3 trial of the drug in H1 2023.

SunCor shares have now lost about half of their value today already while analysts continue to have a Strong Buy consensus rating for the stock alongside an average price target of $62.67.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More